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Introduction
The potential role of adjuvant therapies in enhancing
the efficacy of recombinant human erythropoietin
(epoetin) in patients receiving regular dialysis has
received increasing attention in recent years.1,2 The
important reason for adjuvant therapies is that they
may help to reduce epoetin requirements or allow
dialysis patients to achieve increased hemoglobin con-
centrations, and derive more cost-effectiveness and
greater clinical benefits from epoetin treatment. Recent
research highlights how the use of such epoetin adju-
vants as vitamin C (ascorbic acid, ascorbate), iron, an-
drogens and L-carnitine has the potential to improve
the efficiency of anemia therapy in patients with kidney
diseases.3 Vitamin C could act as a temporary iron
chaperone through its chelating characteristic. Sixteen
published studies during the past decade have addressed
this issue.4–19 Administration of intravenous (IV) vita-
min C to hemodialysis patients with functional iron
deficiency may promote better anemia control and iron
utilization. This promising effect for ameliorating poor
response to epoetin can be observed not only for
hemodialysis patients having a high ferritin level of
> 500 to 800 µg/L,4–13 but also for those with normal
iron status.7
Intravenous Vitamin C Improves 
Epoetin Responsiveness
In the first report about hemodialysis patients on
epoetin therapy,4 IV vitamin C improved hemoglobin
response to epoetin in 4 patients with iron overload.
Subsequently, several clinical studies by Tarng et al8–10
and other investigators5–7,11 reported an apparent ben-
eficial effect of high-dose IV vitamin C in terms of a
13–24% increase in hemoglobin concentrations or a
10–32% increase in hematocrit levels and/or a 0–24%
reduction in epoetin doses (Figure 1). Doses of 300mg
and 500 mg IV vitamin C 3 times a week have been
used with similar efficacy,4–11 although most were small,
short-term studies that were not appropriately con-
trolled or randomized. Nevertheless, the recent studies
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by Keven et al7 and Attallah et al11 seem to have been
well designed and substantiate the findings of earlier
investigations and the less rigorously controlled trials.
IV vitamin C is not suggested as a cure for all
hemodialysis patients, and Tarng et al10 and other
investigators6,7 reported that about 49–83% of the
patients were responsive to IV vitamin C. Keven et al7
further observed that hemoglobin responses to vita-
min C were the same in patients with iron overload
and those with normal iron status, but the response
rate (83%) tended to be greater in the former (59%).
Mechanisms of Vitamin C to Combat
Epoetin Hyporesponsiveness
Vitamin C, a reducing agent, is able to release iron
from ferritin and mobilize iron from the reticuloen-
dothelial system to transferrin.20,21 This leads to an
increase of iron utilization in the erythrons. Tarng 
et al19 demonstrated a decrease in serum levels of sol-
uble transferrin receptor with a parallel rise in transferrin
saturation (TSAT) within 7 days in patients receiving
2,000 mg IV vitamin C, indicating it was probably
through alterations in intracellular iron metabolism.
Although there is no concrete evidence to support
this contention, 10 observations are at least compati-
ble with it.4–13 Most studies have shown a 6–15% rise
in TSAT4–13 and a 5–31% reduction in serum ferritin
concentrations5,6,10,12,13 following administration of
IV vitamin C to hemodialysis patients (Figure 2).
Other explanations for the positive effect of vitamin C
on epoetin responsiveness include amelioration of
oxidative stress and inflammation. Cumulative data
show that vitamin C treatment is effective in palliating
hemodialysis-induced oxidative stress, as indicated by
lipid peroxidation,22,23 and by hemolysis and over-
expression of proinflammatory cytokines.22 There are
concerns that vitamin C promotes electron exchanges
and it can be shown in vitro to enhance iron toxicity
to cellular constituents. However, our study showed
no compelling evidence for a pro-oxidant effect of
vitamin C supplementation on DNA oxidative damage
in hemodialysis patients.24 The most recently reported
study by Attallah et al11 also showed that improve-
ment in erythropoiesis was associated with a signifi-
cant decrease in C-reactive protein levels in patients
treated with IV vitamin C. Since vitamin C is a well-
known antioxidant, its effect on erythropoiesis may
have arisen from this property.
Potential Problems of Vitamin C
Treatment in Dialysis Subjects
Major concern regarding safety of vitamin C supple-
mentation arises from its metabolism to oxalate,
which may lead to tissue deposition of calcium oxalate
crystals by exceeding the threshold of its solubility,
and eventually increase cardiovascular risks in uremic
patients. As in most of the previous works on epoetin
adjuvant therapy, vitamin C at dosages many times
higher than that suggested for the general population
became recommended in dialysis patients, without
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Figure 1. Intravenous vitamin C effects on hemoglobin (Hb) response (gray bars) and epoetin (EPO) dose (white bars) in patients 
receiving hemodialysis.
putting evidence forward to demonstrate the safety in
terms of oxalate metabolism.4–7,11–17 In the studies by
Tarng et al,8,10 there was a modest increase in plasma
oxalate levels after 8 weeks of IV (900 mg per week)
vitamin C treatment. A small uncontrolled study fur-
ther showed an increase in serum oxalate levels by
12% or 18% from baseline in patients treated with IV
(750 mg per week) and oral (1,750 mg per week)
vitamin C for 8 weeks, but no significant changes in
LV function or renal calculi formation.16 The long-term
risks for vitamin C-induced oxalosis remains to be deter-
mined, since these generally short-term studies8,10,16
were too small to detect infrequent adverse events.
Low-dose IV or Oral Vitamin C
Treatment
To reduce the risks of oxalosis induced by high-dose
vitamin C, treatment options with low-dose IV or
oral vitamin C may be considered if both could be
proved safe and effective. The efficacy of IV vitamin
C at doses of < 900 mg weekly has been evaluated in 
3 small, non-randomized studies. A dose of 100 mg
or 200 mg IV 3 times a week has shown some prom-
ise in reduction in epoetin doses or a rise in hematocrit
levels in 2 clinical trials,12,13 but the effect was not
demonstrated in another one.14 Canavese et al further
showed a significant increase in plasma oxalate levels,
from 35.6 µmol/L to 39.5 µmol/L and 50.3 µmol/L,
with IV vitamin C 250 mg and 500 mg weekly, respec-
tively.25 Calcium oxalate supersaturation occurred in
40% of patients during 6 months’ therapy with 500 mg
weekly. Oral vitamin C can augment absorption of iron
from the gastrointestinal tract. Theoretically, functional
iron deficiency might be overcome by oral vitamin C
substitution in patients with iron overload as it was by
IV vitamin C. However, most of the clinical studies
using oral vitamin C formulas failed to increase iron
utilization or improve epoetin responsiveness in he-
modialysis patients.15–17 Exceptionally, a small uncon-
trolled study found that oral use of vitamin C with
iron could increase hematocrit and serum iron levels
in hemodialysis patients, but the data on epoetin dose
change were not mentioned.8 Collectively, the litera-
ture implies possible efficacy for low-dose IV vitamin
C as an adjuvant therapy, but the body of evidence is
not definitely conclusive.
Recommendations
Vitamin C has not been evaluated in peritoneal dialysis
or chronic kidney disease patients. The optimal dose
frequency and duration of vitamin C therapy remain
to be established. So far, there are still gaps between
theoretical knowledge and actual demonstration of
benefits of vitamin C as an epoetin adjuvant in major
outcomes, i.e. improvement in erythropoiesis,4–19,26
reduction in cardiovascular mortality,27 amelioration
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Figure 2. Intravenous vitamin C effects on transferrin saturation (TSAT) changes (gray bars) and serum ferritin changes (white bars) in
patients receiving hemodialysis.
of endothelial dysfunction,28 and complications asso-
ciated with secondary oxalosis. The ratio between
unknown benefits and known side effects should be
carefully evaluated to maintain the imperative of pri-
mum, non nocere. Unfortunately, many opinions about
the utility of this agent in hemodialysis patients are
often based on either small, short-term uncontrolled
studies or cross-sectional observations. To obtain evi-
dence for future guidelines, we clearly need additional
long-term, adequately sized, randomized controlled
studies evaluating the efficacy and safety of vitamin C
to better define the appropriate clinical role, if any, of
this therapy. However, in hemodialysis patients with
poor response to epoetin if other factors have been
corrected or excluded, it is reasonable to start these
patients on 100 mg vitamin C IV administered at the
end of hemodialysis 3 times a week for 2–6 months. If
no response is seen, the dose should be titrated up to
a dose of 300 mg or 500 mg IV 3 times a week for
2–6 months with careful monitoring of potential tox-
icity. Once serum ferritin falls to 300 µg/L, vitamin C
therapy should be stopped and IV iron administration
begun.9
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